Is 0.5mg Semaglutide Enough to Produce Meaningful Weight Loss?

Where 0.5mg sits in the evidence base

The clinical trial that underpins Wegovy's UK licence for weight management is STEP 1, published in the New England Journal of Medicine. Participants received 2.4mg semaglutide weekly at maintenance (not 0.5mg) and achieved an average body-weight reduction of around 15% over 68 weeks alongside lifestyle changes. The lower doses used during titration were not studied as long-term maintenance levels; they exist so the body adjusts to the medicine gradually, keeping GI side effects manageable. 0.5mg is the second rung: it follows the 0.25mg opener and runs for roughly four weeks before the prescriber considers moving to 1.0mg. The NHS semaglutide medicines page reflects this schedule, describing the dose increases as steps toward the maintenance level rather than treatment endpoints in themselves. So the honest answer to whether 0.5mg is enough is: enough for what? For tolerability, yes. For the weight-loss outcomes described in the trial data, the evidence points firmly to higher doses.

What you might notice, and what it means

Some people do experience a reduction in appetite at 0.5mg, and a small amount of early weight loss at this stage is not unusual. That is not the dose doing nothing; it is the medicine beginning to work on GI hormones and appetite signalling. What the evidence does not support is the idea that 0.5mg produces the kind of sustained, clinically meaningful weight loss associated with the maintenance doses. If your weight has plateaued at 0.5mg, that is expected rather than a sign the medicine is not right for you. The full semaglutide dosing schedule shows clearly that the stepped approach is designed to get you to maintenance, not to keep you here. Side effects also tend to be most noticeable at each new level (nausea, occasional loose stools, reduced hunger) and typically ease within a couple of weeks of staying at the same dose. If they have not settled, that is a conversation for your prescriber rather than a reason to stay at 0.5mg indefinitely.

When staying at 0.5mg longer makes clinical sense

There is no fixed rule that says you must move to 1.0mg after exactly four weeks. If side effects at 0.5mg are still significant, a prescriber may recommend staying a further four weeks before the next increase. That flexibility is built into the schedule deliberately. What the guidance does not support is remaining at 0.5mg as a permanent treatment level, the dose is simply too low to deliver the outcomes the medicine is licensed and studied for. Thinking about whether 1.0mg will be enough is a reasonable next question, and the pattern is similar: 1.0mg is itself an intermediate step, not the maintenance level for most people. The destination the evidence points toward is 2.4mg weekly, and now with the MHRA-approved 7.2mg option for those who need it, the ceiling has moved higher still. Cost is sometimes a consideration here too, if you want context on where to buy Wegovy in the UK and what to look for in a legitimate provider, that is worth reading alongside any dose questions.

Having the conversation with your prescriber

If you are mid-titration and uncertain, the most useful thing you can do is raise it with whoever prescribed your treatment. At nume, every repeat order goes through a fresh clinical review (a real prescriber reads your update, not an automated system) so the question of whether your dose is right for you gets looked at each time, not just at the start. If you have not yet started treatment and are trying to understand how Wegovy doses work before committing, our prescribers are used to explaining this in plain terms. A consultation is free, there is no subscription, and you are not obliged to proceed. The weight-loss treatments page is the place to begin if you want to speak to our clinical team, you can also read more about semaglutide at the 0.5mg level specifically if you want the detail before you do. Worth knowing: these are prescription-only medicines and the dose you end up on is always a prescriber's decision based on your response, not a number chosen in advance.